Skip to main content scroll back to top of page

Chimerix is now part of Jazz Pharmaceuticals. Learn more at www.jazzpharma.com

Chimerix Logo

Utility Navigation

Chimerix Logo

Primary Navigation

Close Menu
  • Patients
    • Expanded Access
    • Clinical Trials
  • About Imipridones
    • About Impipridones
      About ImpipridonesImipridones

      Oncology: Imipridones

      • ONC201 dordaviprone for gliomas
      • ONC206 for central nervous system tumors
      • ONC212 IND-enabling studies
      PublicationsNeuro Oncology Publications2024 SNO Annual Conference
  • Careers
  • Contact

Contact Us

Chimerix, Inc.
2505 Meridian Parkway, Suite 100
Durham, NC 27713
Phone: 1-919-806-1074
Fax: 1-919-806-1146

Chimerix IRL Limited
10 Earlsfort Terrace
Dublin
Post Code 2
Ireland

Follow us on X @JazzPharma

Find us on LinkedIn

Clinical Trials:

[email protected]

Investor Relations:

[email protected]

Media Inquiries:

[email protected]

Human Resources:

[email protected]

Expanded Access Program:

[email protected]


Chimerix Logo
  • Chimerix on LinkedIn
  • Chimerix on Twitter

Legal Menu

  • Privacy Notice
  • Cookie Notice 
  • Terms & Conditions of Use
  • Forward-Looking Statements
  • Community Guidelines

© 2025 Copyright Chimerix. All rights reserved.

We are pleased to share that a new treatment for H3 K27M-mutant diffuse midline glioma received FDA accelerated approval. This milestone is a meaningful advancement in the treatment of an ultra-rare and aggressive brain tumor, which primarily affects children and young adults.

Select Jazz to learn more about our latest news in H3 K27M-mutant diffuse midline glioma.
Select continue to proceed to the Chimerix website

Jazz